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Abstract 
GABA plays a key role in both embryonic and neonatal brain development. For 
example, during early neonatal nervous system maturation, synaptic 
transmission, mediated by GABAA receptors (GABAARs), undergoes a 
temporally specific form of synaptic plasticity, to accommodate the changing 
requirements of maturing neural networks. Specifically, the duration of 
miniature inhibitory postsynaptic currents (mIPSCs), resulting from vesicular 
GABA activating synaptic GABAARs, is reduced, permitting neurons to 
appropriately influence the window for postsynaptic excitation. 
Conventionally, programmed expression changes to the subtype of synaptic 
GABAAR are primarily implicated in this plasticity. However, it is now evident 
that in developing thalamic and cortical principal- and inter-neurons an 
endogenous neurosteroid tone e.g. allopregnanolone, enhances synaptic 
GABAAR function. Furthermore, a cessation of steroidogenesis, due to a lack of 
This is the peer reviewed version of the following article: 'Endogenous neurosteroids influence 
synaptic GABAA receptors during post-natal development', Journal of Neuroendocrinology, 
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substrate, or a co-factor, appears primarily responsible for early neonatal 
changes to GABA-ergic synaptic transmission, followed by further refinement, 
which results from subsequent alterations of the GABAAR subtype. The timing 
of this cessation of neurosteroid influence is neuron specific, occurring by 
postnatal day 10 (P10) in thalamus, but about a week later in cortex. 
Neurosteroid levels are not static, but change dynamically in a variety of 
physiological and pathophysiological scenarios. Given that GABA plays an 
important role in brain development, abnormal perturbations of neonatal 
GABAAR-active neurosteroids, may have a considerable immediate, but also 
longer term impact, upon neural network activity. Here we review recent 
evidence that changes in neurosteroidogenesis substantially influence 
neonatal GABA-ergic synaptic transmission. We discuss the physiological 
relevance of these findings and how interference of neurosteroid-GABAAR 
interaction early in life may contribute to psychiatric conditions later in life.  
 
Introduction 
From an early embryonic age, GABA-ergic signalling plays a fundamental role in 
neuronal development, influencing neuronal proliferation, migration and 
differentiation and is important in the establishment of neuronal networks1–4. 
These effects of GABA are mediated by ionotropic GABAA receptors (GABAARs), 
or by G-protein coupled GABAB receptors. Certain steroids are potent, 
endogenous, positive allosteric modulators (PAMs) of the GABAAR5–8 
(neuroactive steroids). Furthermore, such steroids may be synthesised locally 
in the brain, or spinal cord and are classed as neurosteroids. Here we consider 
the role of neurosteroids and GABA in the developing neonatal central nervous 
system (CNS). 
Neurosteroids: endogenous modulators of the GABAAR. 
The finding in 1966 by Craig and colleagues that the anticonvulsant properties 
of certain endogenously occurring steroids could be distinguished from 
classical hormonal actions9, paved the way nearly two decades later to the 
discovery that the synthetic general anaesthetic steroid alphaxalone10 and 
subsequently certain endogenous metabolites of progesterone (5α-pregnan-
3α-ol-20-one; allopregnanolone) and deoxycorticosterone (5α-pregnan-3α,21 
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diol-20-one; 5α-THDOC) act as potent and selective positive allosteric 
modulators (PAMs) of the major inhibitory receptor in the mammalian brain, 
the GABAAR5,10–14 (Figure 1). 
GABAARs belong to the transmitter-gated ion channel superfamily and are 
composed of five subunits arranged around a central pore to form an anion-
conducting ion channel15,16. Low nM aqueous concentrations of these 
neuroactive steroids enhance the actions of GABA by promoting the anion-
conducting state of the associated channel11,14,17,18. Their activity at such low 
concentrations suggests the presence of a high affinity steroid binding site on 
the GABAAR. However, these steroids are highly lipophilic, resulting in 
relatively high membrane concentrations in close proximity to the proposed 
transmembrane binding site on the GABAAR19,20 . Therefore, the steroid may 
have a relatively low affinity for the receptor, but be optimally concentrated, 
locally in the membrane, leading to an increased probability that the steroid 
will occupy the receptor binding site19,20. The GABAAR is the target for clinically 
important drugs, e.g. benzodiazepines and certain general anaesthetics, which 
enhance the GABAAR function 5. In common with such drugs, administration of 
neuroactive steroids produce anxiolytic, analgesic, anticonvulsant and sedative 
effects, with higher doses capable of inducing a general anaesthetic state5,8.  
Initially, endocrine glands such as the adrenals and ovaries were considered 
the exclusive source of steroid, necessitating it to cross the blood brain barrier 
to influence neural activity. Subsequently, compelling evidence emerged for de 
novo brain synthesis i.e. neurosteroids21. Hence, these endogenous GABAAR-
modulators may potentially act in an endocrine, paracrine, or autocrine 
manner, to influence neuronal signalling in various physiological and 
pathological situations. Indeed, neurosteroid levels are dynamically changed in 
a variety of physiological (e.g. development, puberty, pregnancy, stress, 
ovarian cycle) and pathophysiological (e.g. major depression, postpartum 
depression, premenstrual tension, panic attacks and schizophrenia) scenarios 5.  
In the brain and spinal cord the GABAAR-active steroids such as 
allopregnanolone and 5α-THDOC may a) originate from peripheral sources e.g. 
placenta, ovaries and adrenals necessitating them crossing the blood brain 
barrier22; b) be derived from their peripheral hormonal precursors, 
progesterone and deoxycorticosterone, or c) be synthesised de novo from 
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cholesterol via a series of multi-enzymatic steps23. Diverse approaches 
including in situ hybridization, immunohistochemistry, gas chromatography 
mass spectrometry, electrophysiology and behaviour, purport that 
neurosteroids, synthesised by neurons and/or glia may achieve levels sufficient 
to influence in a paracrine and/or autocrine fashion GABAAR signalling from the 
onset of embryonic GABAergic transmission into maturity 5,24–29. The suite of 
enzymes that synthesise neurosteroids exhibit regional and cellular-selective 
expression patterns, which change within discrete temporal windows and are 
susceptible to external challenges, e.g. stress23,30–33. In the CNS the production 
of GABAAR-active neurosteroids from cholesterol (Figure 1) first requires the 
translocation of the steroid across the mitochondrial membrane by 
translocator protein 18 kDa (TSPO)34,35. Cholesterol is then metabolised to 
pregnenolone by the mitochondrial P450 side-chain cleavage enzyme 
CYP11A1, this metabolite is then exported across the mitochondrial 
membrane, where it may be converted to GABAAR-active neurosteroids such 
as allopregnanolone following three sequential enzyme reactions catalysed by 
3β-hydroxysteroid dehydrogenase (3β-HSD) to form progesterone, 5α-
reductase (5α-R) to produce 5α-dihydroprogesterone (5α-DHP) and 3α-
hydroxysteroid dehydrogenase (3α-HSD) to form allopregnanolone (Figure 1) 7. 
Note both in the CNS and the periphery the enzymes 5α-R and 3α-HSD may 
sequentially participate in the conversion of deoxycorticosterone derived 
primarily from the adrenals into the GABAAR-active 5α-THDOC 22. We have 
recently reviewed the expression of 5α-R and 3α-HSD in mammalian brain24, 
(see also 30-33). As GABA plays a crucial role in neurodevelopment, during this 
critical time of neonatal development it is conceivable that the changing levels 
of neurosteroids, from CNS-located paracrine, or autocrine sources, may 
influence the establishment of mature neuronal circuits and communication. 
Additionally, neonatal endocrine glands such as the adrenals may provide the 
brain and spinal cord with either the GABAAR-active steroids per se, or their 
precursors 22,36,37. 
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GABAARs. 
The GABAAR subunits are drawn from a repertoire of 19 gene products 
belonging to distinct families including: α1-6; β1-3; γ1-3, δ, ε, θ, π and ρ1-315,16. 
In the adult mammalian brain this diversity underpins the expression of 20-30 
GABAAR subtypes, that are uniquely distributed and consequently influence 
particular behaviours38–40. Although neuroactive steroids are highly selective 
for GABAARs, they exhibit limited GABAAR subtype selectivity5. However, the 
GABAAR subunit composition does influence a) neuronal subcellular location 
e.g. synaptic vs extra/peri-synaptic expression 41 b) the impact of enzymes (e.g. 
kinases) upon receptor function/location/expression42–44, c) the pharmacology 
of the receptor e.g. benzodiazepines and certain general anaesthetics15,40 and 
d) the physiological properties of the receptor, including the kinetics of 
receptor activity influenced by rates of deactivation, desensitization, and GABA 
affinity42.  
The neuronal location of the receptor influences the GABA inhibitory signalling 
repertoire of the neuron. Receptors clustered in the post-synaptic domain 
primarily serve to mediate a fast, phasic form of inhibition in response to 
relatively high local concentrations of neurotransmitter, which occur in the 
synapse following the vesicular release of GABA41. By contrast, receptors in 
peri-synaptic and extra-synaptic locations are activated by ambient 
concentrations of GABA to mediate a sustained, or tonic form of neuronal 
inhibition41. However, in some neurons during physiological bursts of high 
frequency presynaptic stimulation the spill-over of GABA from the synapse is 
sufficient to additionally engage these extrasynaptic receptors to produce a 
greatly prolonged form of slow phasic inhibition45–47. The majority of GABAARs 
contain two α and two β subunits together with a single copy of the γ2 subunit. 
Synaptic receptors often contain the γ2 subunit, although receptors 
incorporating this subunit may be located out with the synapse. Receptors 
incorporating the δ subunit, in place of the γ2 subunit are expressed extra- or 
peri-synaptically41,42,48,49. 
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GABAAR subunit expression and function during embryonic and post-natal 
development. 
In the adult brain, activation of GABAARs usually causes an inhibitory effect on 
neuronal excitability, conferred both by a net inward directed flow of Cl- ions 
and the shunting action of GABA50. However, early in development (embryonic 
and first postnatal week), GABAAR activation results in neuronal depolarization, 
due to a relatively high intracellular Cl- concentration, resulting from limited 
expression of KCC2, the principal neuronal transporter for Cl- ion extrusion51. 
Although the validity of this developmental ionic perturbation has been 
challenged, under certain experimental conditions52–54, the depolarizing nature 
of these early GABA-ergic signals may be sufficient to activate voltage-
dependent calcium, or sodium channels and appear pivotal to the 
neurotrophic actions of the neurotransmitter55–57. Furthermore, during 
embryogenesis, such depolarizations are primarily mediated by activation of 
extra-synaptic GABAARs, which are expressed prior to and indeed facilitate the 
establishment of functionally relevant synaptic connections after birth2,3. 
During early development the subunit composition of GABAARs is highly plastic, 
consequently impacting upon the physiological and pharmacological properties 
of the receptors and influencing their subcellular localization15,42. Preceding the 
generation, migration, and differentiation of most telencephalic and 
mesencephalic neurons58,59, the first detection of GABAAR subunits (including 
α1-5, β1-3 and γ1-3), coincides with the appearance of GABA-positive neurons 
at approximately E13-14 in the marginal zone, sub-plate, and sub-ventricular 
zone60,61. For rodent brain, the end of the first postnatal week generally signals 
a change to a hyperpolarizing GABAAR response1. Depending on the specific 
brain region, postnatal weeks two to three mark the establishment of a near-
mature synaptic network, which reaches an adult stage by about two months 
of age following sexual maturation. From approximately the end of the first 
postnatal week synaptic GABAAR signals, resulting from the vesicular release of 
GABA, begin to play an important role in shaping the development of neuronal 
circuits62. 
 
 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
As the postnatal brain develops there is an increased requirement for temporal 
precision within neuronal networks and accordingly, in many neurons the 
duration of phasic events e.g. miniature inhibitory postsynaptic currents 
(mIPSCs) mediated by the activation of synaptic GABAARs by GABA released 
from a single vesicle, is progressively reduced42,63–69. This critical development 
of GABA-ergic signalling is generally considered to result from a genetically 
programmed change of the subtype of synaptic GABAAR. In this regard the α-
subunit isoform exerts a profound role on the duration of GABAAR-mediated 
phasic events. For example, electrophysiological studies with expressed 
recombinant GABAARs demonstrates the duration of GABA-evoked currents 
mediated by receptors incorporating either α2-, or α3-subunits are prolonged 
compared to equivalent receptors containing the α1 subunit70, although the β 
and γ subunit isoforms may also influence the mIPSC decay71,72. Of 
physiological relevance, in different neurons (e.g. principal glutamatergic 
neurons and GABAergic interneurons) expression of different synaptic GABAAR 
isoforms results in kinetically distinct synaptic events, underpinning the 
integration of neuronal signals and network activity and allowing the 
establishment of behaviourally relevant neuronal rhythms73,74. 
Many neurons express multiple GABAAR isoforms, complicating evaluation of 
their role in neonatal development. To study this in detail we have used the 
ventrobasal (VB) neurons of the mouse thalamus. These neurons provide an 
ideal model as they exhibit a clear developmental transition from synaptic α2-
GABAARs from postnatal weeks 1-2, to α1-GABAARs in weeks 2-375 (Figure 
2).They are innervated by a band of GABA-ergic neurons, the nucleus 
reticularis (nRT neurons), which release GABA onto the VB neurons. Our 
studies, described below, reveal an important role for GABA-modulatory 
neurosteroids in determining the duration of mIPSCs during neonatal 
development.  
 
During postnatal development of thalamic VB neurons neurosteroids, in concert 
with changes to GABAAR isoforms, influence phasic and tonic inhibition. 
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We reported that the duration of thalamocortical VB neuron mIPSCs is greatly 
reduced over a critical, short period of 1-2 days between postnatal days (P) 9-
1175. Synaptic receptors incorporating the α1-subunit are associated with brief 
mIPSCs63,75. Implicating changes to synaptic GABAARs, our 
immunohistochemical and electrophysiological studies with an α1 “knock-out” 
mouse and benzodiazepine-insensitive knock-in (α1H101R; α2H101R) mice 
revealed P20 neurons to exclusively express synaptic α1βγ2 GABAARs, whilst 
younger mice expressed the α2βγ2 isoform75 (Figure 2). However, the major 
change to the mIPSC duration, occurred prior (P9-11) to the synaptic α2- to 
α1-GABAAR transition 75 and were replicated in an α1-/- mouse75. Clearly, this 
initial P9-11 synaptic plasticity does not result from expression of α1-
GABAARs75. During postnatal development the levels of GABAAR-modulatory 
neurosteroids change76. Do neurosteroids influence neural inhibition during 
postnatal development (P7-24)? 
Preventing neurosteroid synthesis in P7 thalamus with the 5α-reductase 
inhibitor finasteride significantly reduced mIPSC duration77. Intracellular 
delivery of the neurosteroid scavenger γ-cyclodextrin [γ-CD]78–80, produced the 
same effect77, but by P10 was inert (Figure 2,3). Exogenous 5α3α was equi-
effective in prolonging mIPSCs of P7 and P20-24 neurons. Therefore, the 
developmental change in the mIPSCs is not a consequence of synaptic 
GABAARs steroid-insensitivity, but results from a loss of the neurosteroid77. 
Note that the duration of both control and γ-CD-treated P20-24 mIPSCs are 
further reduced c.f. P10 mIPSCs, a change which corresponds temporally with 
the exchange of synaptic α2-GABAARs by α1-GABAARs77 (Figure 2). Hence, prior 
to P10 the mIPSC duration is reduced, caused by decreased neurosteroid 
levels, with subsequent further kinetic refinement resulting from a change in 
the synaptic GABAAR subtype (Figure 2). A recent study suggested that 
hippocampal expression of the GABAAR α2-subunit was increased by GABAAR-
active neurosteroids81. Therefore, it is conceivable that a waning neurosteroid 
tone heralds the programmed subsequent loss of thalamic synaptic α2-
GABAARs post P10. 
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The source of the neurosteroid influencing P7-8 neurons is not known. Studies 
using an antibody against the neurosteroid suggest that the VB neurons 
contain 5α3α82. Inclusion in the recording pipette of the membrane-
impermeant γ-CD (0.5 mM), caused a time-dependent (> 6 min) decrease in 
the mIPSC duration of P7 VB neurons, mirroring the effect of pre-incubated γ-
CD and of finasteride pre-treatment77. These studies demonstrate that VB 
neurons contain GABAAR-active neurosteroids, but do not elucidate whether 
their source is autocrine, paracrine, or indeed a consequence of prior 
endocrine release5.  
We suggest that by P10 the local neurosteroid levels are insufficient to 
influence GABA-ergic neurotransmission. Can the more mature thalamus 
synthesise neuroactive steroids? Incubation of thalamic slices with 5α-DHP, 
the immediate precursor of allopregnanolone (Figure 1), caused a substantial 
prolongation of mIPSCs of both P20-24 and P7 neurons77, which was prevented 
by indomethacin, an inhibitor of 3α-hydroxysteroid dehydrogenase (3α-HSD), 
the enzyme that converts 5α-DHP to the GABAAR-active allopregnanolone 
(Figure 1). Although indomethacin is not a selective inhibitor of the 3α-HSD 
enzyme, this effect of 5α-DHP to prolong the mIPSCs was reversed by γ-CD 
treatment. Collectively, these results demonstrate that the more mature (P20-
24) thalamic slice retains the ability to synthesise GABAAR-active neurosteroids 
and that the change in mIPSC duration at P9-10 results from a loss of steroid 
substrate, or a co-factor e.g. NADPH, see83. 
P20-24 VB neurons express synaptic α1β2γ2 and extrasynaptic α4β2δ GABAARs 
that mediate phasic and tonic inhibition respectively75,84. Although the P20-24 
mIPSCs were insensitive to γ-CD treatment, suggesting that local neurosteroid 
levels are insufficient to impact upon synaptic GABAARs, neurosteroids are 
particularly efficacious upon recombinant receptors incorporating the δ-
subunit85,86. However, the magnitude of the thalamic tonic current mediated 
by α4β2δ-GABAARs was not influenced by γ-CD pre-incubation, suggesting that 
in P20-24 VB neurons the neurosteroid levels are not sufficient to influence 
either synaptic, or extrasynaptic GABAARs77. Nevertheless, incubation with the 
precursor 5α-DHP, resulted in a large increase of the tonic current, illustrating 
that neurosteroid production can be reinitiated sufficiently to influence both 
phasic and tonic inhibition77. 
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The mIPSC frequency of P10-24 VB neurons was much greater than that of P7 
neurons. Unexpectedly, incubation with finasteride greatly increased the 
mIPSC frequency of P7, but not of P10 VB neurons. Furthermore, 5α-DHP 
greatly reduced the mIPSC frequency of P20-24 VB neurons, an effect probably 
mediated by allopregnanolone, as indomethacin prevented this suppression of 
vesicular release by 5α-DHP. Hence, vesicular GABA release from P7 nRT 
neurons is governed by a neurosteroid tone which, as it wanes, results in an 
increased mIPSC frequency for P10-24 neurons77. These effects of the steroid 
metabolite appear unlikely to be mediated by presynaptic nRT GABAARs as 
other enhancers of GABAAR function (pentobarbital, etomidate and zolpidem) 
had no effect on quantal GABA release77 and therefore the steroid may act via 
alternative targets e.g voltage-gated T-type calcium channels87.  
 
A neurosteroid influence on GABA-ergic transmission of the developing mouse 
cortex. 
Given the sudden loss of neurosteroid influence for P10 VB neurons we 
investigated whether GABA-ergic transmission in another brain region was 
similarly influenced and if so determine whether the temporal neurosteroid 
profile was similar to thalamus. These thalamic relay VB neurons send 
projections to cortical layer 4 (L4) neurons during P4-8 and subsequently (P10-
14) L4 cortical neurons project to L2/3 neurons88,89. We therefore investigated 
in L2/3 pyramidal neurons and GAD-67+ cortical interneurons the temporal 
profile of phasic inhibition and the influence of neurosteroid tone.  
In L2/3 cortical pyramidal neurons the mIPSC profile changed considerably 
from neonatal (P7-15), to juvenile stages (P20-24)90. Similar to VB neurons, the 
mIPSC frequency increased and their duration decreased between P7-8 and 
P20-24. In common with VB neurons, the mIPSC kinetic change did not result 
from neurosteroid insensitivity of synaptic GABAAR, but resulted from a loss of 
neurosteroid production as the mIPSC decay time of P7, but not of P20-24 
cortical neurons was substantially reduced by pre-incubation with γ-CD, or by 
finasteride pre-treatment90. In contrast to the thalamic VB neurons, γ-CD 
influenced the mIPSC decay time at P10 and at P15, but as described above 
was inert by P20-24 (Figure 3). Hence, the neurosteroid profile is temporally 
distinct from that of the thalamocortical relay neurons. Mirroring the VB 
neurons, incubation of the cortical slice with 5α-DHP greatly prolonged mIPSCs 
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of P20-24 pyramidal neurons. In common with thalamic VB neurons, this effect 
of 5α-DHP was prevented by indomethacin and reversed by γ-CD treatment. 
Collectively, these results demonstrate that when supplied with the immediate 
steroid precursor, the cortical slice can metabolise 5α-DHP into a GABAAR-
active neuroactive steroid90. Indeed, phasic inhibition in hippocampal dentate 
gyrus granule cells and the medium spiny neurons of the nucleus accumbens is 
similarly influenced by 5α-DHP (unpublished), suggesting this capacity to 
synthesise GABAAR-active neurosteroids may be a common feature across 
different brain regions.  
Even in the presence of γ-CD, the mIPSC decay time decreased from P7-8 to 
P20-24 suggesting synaptic GABAARs to be influenced by additional factor(s) 
during neonatal development. As described above, the GABAAR subunit 
composition may influence the mIPSC duration, with particularly the α1 
subunit associated with brief events. We found the mIPSCs recorded from α1-/- 
cortical L2/3 pyramidal neurons to be prolonged c.f. their wild type 
counterparts at all ages studied (P7-8, P10, P15 and P20-24)90. In common with 
WT neurons, treatment with γ-CD, or finasteride, reduced the mIPSC decay 
time of P7-15 α1-/- neurons, but with no effect on P20-24 neurons (Figure 3). 
Therefore, during cortical neuron development from P7, to at least P15, the 
duration of phasic inhibitory events is simultaneously influenced by a 
neurosteroid tone and by the subunit composition of the synaptic GABAARs, 
with a waning influence of the neurosteroid occurring between P15 and P20. 
By contrast, for thalamocortical neurons the neurosteroid influence dissipates 
by P10, but the mIPSC duration continues to decrease up to P20-24 due to the 
exchange of synaptic α2-GABAARs by α1-GABAARs (Figure 2,3). Finally, the 
frequency of mIPSCs increased during development in both cortical and 
thalamic neurons. However, whereas in thalamus the increased mIPSC 
frequency was due to a waning neurosteroid presynaptic influence, the 
frequency of cortical mIPSCs was not influenced by γ-CD pre-treatment90 and 
therefore may reflect increased GABA-ergic innervation. 
Immunohistochemical and in situ hybridisation studies reveal cortical principal 
neurons to express both the 5α-reductase and the 3α-HSD enzymes required 
for allopregnanolone synthesis, whereas interneurons do not30. We therefore 
investigated whether phasic inhibition of cortical GABA-ergic interneurons is 
similarly influenced by neurosteroids during neonatal development. 
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Recordings were made from GAD67 GFP+ mice, engineered to co-express green 
fluorescent protein (GFP) with the GABA-synthesising γ-amino decarboxylase 
(GAD67) enzyme, which identifies, but does not distinguish between the three 
major interneuron classes in mouse cortex (i.e. somatostatin-positive (SS+), 
parvalbumin-positive (PV+), 5-HT3R-positive (5-HT3R+)] interneurons89,91–93. 
Recordings from GFP+ neurons revealed P7-8 mIPSCs to be greatly prolonged 
c.f. equivalent recordings from P20-24 neurons. Intracellular γ-CD reduced the 
P7-8 mIPSC duration, with no effect on P20-24 neurons. Therefore, in common 
with cortical pyramidal neurons, interneuron phasic inhibition is influenced by 
neurosteroids early in postnatal development, an effect that waned by P20-24. 
As these interneurons do not appear to express the enzymes to synthesize 
allopregnanolone, these observations suggest such steroid may originate from 
paracrine, or endocrine sources and not emanate directly from autocrine 
synthesis30. 
 
Neurosteroid modulation of GABAAR function during postnatal development:  
Physiological relevance. 
The findings presented above provide a compelling case for endogenous 
pregnane steroids enhancing GABAAR-mediated phasic inhibition in both 
cortex and thalamus during the 2nd and 3rd post-natal weeks. During early 
postnatal maturation a programmed cessation of neurosteroidogenesis and 
changes to the expression of synaptic GABAAR subtypes, act in concert to 
influence phasic inhibition. This interplay of neurosteroidogenesis with GABAAR 
expression follows a neuron-specific temporal pattern. In somatosensory 
thalamus i.e. VB neurons, the neurosteroid tone dissipates by P10, prior to the 
subsequent exchange of synaptic α2-GABAARs, by α1-GABAARs, which further 
refines phasic inhibition. By contrast, in cortical L2/3 pyramidal neurons a 
neurosteroid influence on phasic inhibition persists for at least another week 
(Figure 3). The fading neurosteroid influence results from a loss of steroid 
substrate, or an essential co-factor, as incubation of P20-24 brain slices with 
5α-DHP prolongs both cortical and thalamic mIPSCs.  
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Neurosteroids enhance the function of both synaptic and extrasynaptic 
GABAARs5,48, thereby potentially influencing both depolarising (embryonic and 
early post-natal) and hyperpolarising (later post-natal) actions of GABA. The 
mechanism(s) that dynamically regulate neonatal neurosteroid levels are not 
known, although NMDA receptor activation reportedly triggers their synthesis 
in CA1 neurons, providing an intriguing link between neural excitation and 
enhancement of neural inhibition94,95. 
What is the physiological significance of these neonatal changes to GABA-ergic 
transmission? As discussed, generally GABA-ergic signals mediate a 
depolarizing response up to the first post-natal week (but see below). Such an 
effect can cause activation of specific voltage-gated conductances, e.g. Ca2+, 
which act to initiate intracellular processes crucial to neuronal migration and 
maturation e.g. neurite growth and synapse formation, thus permitting the 
subsequent establishment and synchronization of neuronal networks2,96,97. 
Neurosteroid levels are elevated during these early phases of 
neurodevelopment, i.e. during late gestation and early neonatal life, but have 
decreased by the third postnatal week, e.g. in the cortex76 (See also Figure. 3 
below).  
The neurosteroid decline coincides temporally with the switch to a 
hyperpolarizing GABA signal1. These events may be associated, as inhibition of 
neurosteroid synthesis, by finasteride, influences KCC2 expression in postnatal 
hippocampus, implying aberrant neuronal inhibition98,99. Is the prolongation of 
the phasic GABA depolarisation by the neurosteroid action required for 
increased KCC2 expression? The differential neurosteroid profile of neonatal 
thalamic and cortical neurons (Figure 3), clearly warrants a comparison of the 
temporal expression of KCC2 in these neurons and the timing of their 
depolarising/hyperpolarising switch. Furthermore, certain cortical 
interneurons are of interest as, even for mature interneurons, GABAAR 
activation may cause their depolarisation100,101, an action important in the 
emergence of brain rhythms in the fast γ- frequency domain102–104 (Figure 3).  
Enhancement by neurosteroids of the GABA-evoked depolarisation may 
influence the temporal window of crucial processes such as neuronal 
migration, morphological maturation and synapse formation3,57. In support, 
allopregnanolone promotes cell proliferation both in human and rodent brain 
and regulates cell-cycle and gene expression105,106. Although some of these 
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actions appear to be mediated by GABAARs, a putative involvement of G-
protein-coupled membrane progesterone receptors requires consideration107. 
Our recordings from neonatal cortical L2/3 pyramidal and GABA-ergic 
interneurons reveal a role for neurosteroids in the normal maturation of the 
cortical network. The formation of functional GABAergic synapses on 
interneurons precedes the development of glutamatergic synapses in principal 
neurons97,108,109, although there are exceptions110–112. Whether neurosteroids 
influence the GABAAR-mediated regulation of both GABAergic and 
glutamatergic transmission in these distinct neuronal types remains to be 
determined. We have not compared in detail the temporal pattern of 
neurosteroid regulation of GABAergic transmission of cortical interneurons, 
with that now established for pyramidal neurons. Furthermore, our recordings 
were from GAD-67+ neurons, therefore the neurosteroid influence may differ 
across distinct GABAergic , SS+, PV+, 5-HT3R+ interneurons89,93,113. The 5-HT3R+ 
interneurons dominate in layers II-III of mature cortex93. However, PV+ 
interneurons may be of particular interest as they exhibit a distinctive, 
extended developmental expression pattern c.f. other interneurons89,114 and a 
window of functional maturation exquisitely susceptible to extrinsic 
modulation during the second to third postnatal week89. In particular, the 
overall homogenous distribution of PV+ interneurons across all cortical layers 
except for layer 193,114 appears crucial for normal development of cortical 
connectivity. Importantly, in schizophrenics (see below) and in animal models 
of this condition, there is a layer selective reduction of the cortical PV and 
GAD67 mRNA signal113.  
Suggesting a putative role for neurosteroids in the development of cortical 
connectivity, neonatal administration of allopregnanolone at (P5), a time which 
precedes the functional maturation of PV+ interneurons and when 
neurosteroids levels are relatively high (Figure 3), alters their distribution 
between superficial (II/III) and deep (V/VI) layers of the adult prefrontal cortex. 
Additionally, allopregnanolone reduces their abundance in the medial dorsal 
thalamus115–117. These neurosteroid effects appear to be GABAAR-mediated as 
they are mimicked by benzodiazepines118. Future genetic and pharmacological 
approaches to manipulate embryonic and postnatal neurosteroids may 
elucidate and differentiate their role in the three main classes of cortical 
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interneurons89. Similar studies are required across different cortical layers and 
areas e.g. visual vs somatosensory cortex, as translaminar GABAergic inhibition 
is sub-served by different interneuron classes119.  
A similar complexity may apply to somatosensory thalamic neurons (e.g. VB 
and nRT), where the neurosteroid influence wanes, approximately a week prior 
to that of cortical pyramidal neurons (Figure 2,3). The significance of this 
temporally distinct neurosteroidogenic profile is not known. However, 
unilateral lesion of neonatal thalamic lateral geniculate nucleus, or the VB, 
substantially alters the developmental expression of α1- and α5-GABAAR 
subunits, across the layers of the corresponding cortical territories i.e. visual, 
V1 and somatosensory, S1, emphasising the profound influence of thalamic 
inputs on the development of cortical GABAergic circuits120. Therefore, it is 
conceivable that thalamic neurosteroidogenesis may influence thalamo-
cortical connectivity.  
Neurosteroids, early life adversity and psychiatric disorders. 
Given the proposed involvement of neurosteroids in brain development, 
experiences that perturb their levels during the establishment of neural 
circuitry, may subsequently influence juvenile and adult behaviour. In support, 
there are significant associations between abnormal levels of GABAAR-active 
neurosteroids e.g. allopregnanolone and a variety of neuropsychiatric 
disorders33 (see below). Moreover, strategies to restore neurosteroid levels in 
such conditions in humans, or equivalent animal models, have proved, 
beneficial33,121–125. Note the majority of psychiatric disorders, ~2/3, are 
diagnosed by 24 years old, or earlier, consistent with a neurodevelopmental 
component126,127. 
Environmental events, grouped under the umbrella of early-life adversity or 
early life stress (ELS), are now recognised as a major preventable cause of 
future psychiatric disorders including anxiety, depression and substance 
abuse128–130. Indeed, prior ELS may additionally be a risk factor for the future 
manifestation of some neurological disorders, e.g. certain forms of epilepsy 131. 
Clinically, these terms describe a variety of negative experiences early in life, 
ranging from poverty, malnutrition, to physical and emotional trauma, or 
abuse132.  
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Patchev and colleagues (1997) first suggested that abnormal regulation of 
neurosteroid action as a consequence of negative experiences early in life 
could affect neurodevelopmental trajectories to contribute to adult 
psychopathology133. In a rodent model of maternal separation the GABAAR-
active neurosteroid (5α-THDOC), administered during early experience of 
reduced maternal care, prevented in adulthood, the development of a variety 
of neuroendocrine dysfunctions and behavioural abnormalities i.e. anxiety, 
associated with prior exposure to early-life adversity133. Whether prior ELS 
subsequently influences adult levels of neurosteroids and/or the dynamic 
regulation of their levels under a variety of physiological conditions e.g. 
pregnancy is not known. However, such experiences greatly influence the 
functional effects of GABAAR-active neurosteroids. Thus, using a naturalistic 
model of fragmented maternal care134,135, we demonstrated that prior ELS 
produces a profound dysregulation of the neuronal circuits orchestrating the 
stress response in the paraventricular nucleus (PVN) of the hypothalamus136. 
Specifically, prior ELS greatly increased the glutamatergic excitatory drive to 
the CRF-releasing PVN neurons, sufficient to prevent the normal suppression 
of PVN firing by physiological levels of allopregnanolone136. Note that 
increased circulating allopregnanolone is purported to act as a part of a 
feedback circuit during acute stress, thereby limiting the duration of CRF 
release and consequently of glucocorticoids21,24. 
The nucleus accumbens is part of the reward pathway and is implicated in both 
depression and drug abuse137–139. In common with thalamus and cortex, it can 
synthesise GABAAR-active neurosteroids (unpublished observations). 
Furthermore, we find that adult mice previously exposed to ELS, exhibit altered 
accumbal GABAAR neurotransmission and an abnormal response to cocaine, 
i.e. an altered locomotor sensitization, a behaviour that recapitulates in 
rodents aspects of drug addiction140.  
Schizophrenia is negatively influenced by early-life adversity141–143. The findings 
by Grobin and colleagues115,116, discussed above, suggest a possible link 
between early neurosteroid dysregulation and an abnormal developmental 
pattern for prefrontal cortex, a region implicated in schizophrenia113. In 
support, a recent investigation revealed abnormal neurosteroid levels in a 
population of schizophrenic patients144. Furthermore, Bortolato and co-
workers have implicated altered neurosteroidogenesis in the accumbal-
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mediated expression of behavioural deficits i.e. altered pre-pulse inhibition, 
which is typically altered in animal models of schizophrenia145. Thus, the 
impact of abnormal neurosteroid levels upon neurodevelopment may extend 
beyond the cortex.  
In conclusion, it is now evident that endogenous neurosteroids play a vital role 
in fine-tuning GABA-ergic transmission during neonatal development in a 
neuron specific manner. GABA is crucial to establishing and developing 
appropriate neural connections in the developing brain. Therefore 
perturbations of neurosteroid levels e.g. by stress, during this critical time of 
neonatal development may have a long term impact upon neuronal circuitry 
and plasticity. Further investigation of the influence of GABAAR-active 
neurosteroids during development is now warranted. Such studies may allow a 
better understanding of the underlying neurobiology that results in the 
psychiatric disorders associated with early life adversity. 
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Figure Legends: 
Figure 1: The schematic illustrates the de novo neurosteroid synthesis. Initially 
cholesterol is translocated across the mitochondrial membrane by TSPO and 
accessory proteins (e.g. VDAC)34,35. The mitochondrial P450scc (CYP11A1) 
converts cholesterol to pregnenolone, which diffuses into the cytosol. Cytosolic 
pregnenolone is subsequently converted to progesterone by 3β-HSD. 
Progesterone, either newly synthesised locally, or of peripheral origin, is 
reduced to 5α-dihydroprogesterone (5α-DHP) and then to allopregnanolone 
(5α-pregnan-3α-ol-20-one, 5α3α) by the enzymes 5α-reductase (5α-R) and 3α-
hydroxysteroid-dehydrogenase (3α-HSD) respectively. Pharmacological agents 
such as finasteride and indomethacin inhibit the enzymes 5α-R and 3α-HSD 
respectively. The agent γ-CD can be employed to sequester the active 
neurosteroid. Although agents such as ethanol and certain antidepressants 
such as fluoxetine are known to enhance the levels of GABAAR-active 
neurosteroids, their specific site(s) of action are not known. TSPO; translocator 
protein, VDAC; the 32-kDa voltage-dependent anion channel (required for 
benzodiazepine binding); 5α-R; 5α-reductase, 3α-HSD; 3α-hydroxysteroid 
dehydrogenase.  
 
Figure 2: Illustrated is a diagrammatic representation of the changing temporal 
influence of an endogenous neurosteroid tone and the GABAAR subunit 
composition upon the decay of mIPSCs recorded from VB neuron during 
development. During early developmental stages [postnatal day (P) 5-P14], the 
mIPSCs are exclusively mediated by α2-GABAAR (blue). By P16, the α2 subunit 
is fully replaced by the α1 subunit (green). During this developmental window, 
mIPSCs recorded from these neurons transition from slow to fast decaying 
phasic events, a trait often associated with a change in the receptor subunit 
composition. However, the developing α2-GABAAR containing VB synapses 
exhibit a significant endogenous neurosteroid tone that profoundly influences 
GABAergic neurotransmission, as indicated by the ability of γ-CD (grey lines) to 
shorten the mIPSC decay time course c.f. control (black line) up to P10. 
Importantly, this kinetic change precedes the switch from α2-GABAARs to α1-
GABAARs. Thus, dissipation of an endogenous neurosteroid tone represents an 
alternative physiological mechanism to impart a rapid kinetic profile to 
GABAergic inhibitory signals. The steroid icon indicates 1) a postsynaptic action 
to enhance the actions of GABA interacting with GABAARs and 2) a presynaptic 
effect of the neurosteroid to suppress the quantal release of GABA mediated 
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by an unknown target. Note that mature α1-GABAAR containing synapses lack 
an endogenous neurosteroid tone.  
 
Figure 3: A schematic representation illustrating the relationship between the 
development of cortical (layers 2 & 3) and the somatosensory thalamic (VB 
complex) connectivity and endogenous neurosteroid levels between P0 and 
P24. Left Y axis: A diagrammatic representation of the temporal profile of the 
development of cortical circuits between postnatal day (P) 0 – P24 describing: 
the oscillatory capacity of the network (green box), interneuron maturation 
(red box) and maturation of cortical neuronal projections for layers (L) 2,3 and 
4 (black box). The Centre Panel illustrates the influence of endogenous 
neurosteroid tone upon GABAAR-mediated phasic inhibition between P0 and 
P20-24, for thalamic VB neurons (blue), L2/3 cortical pyramidal neurons 
(green) and interneurons (red) suggesting a physiologically relevant role for 
endogenous neurosteroids in the processes of developmental maturation: 
representative normalised mIPSCs recorded from VB neurons (blue), L2/3 
cortical pyramidal neurons (green) and interneurons (red) in the presence and 
absence of γ-CD (grey lines) during discrete temporal windows, namely P7, 
P10, P15 and P20-24. The presence of an endogenous neurosteroid tone is 
revealed by the effect of γ-CD (grey lines) on the decay time course (i.e. 
shortening) of the mIPSC (control black lines). This effect of γ-CD is evident at ≤ 
P9 for VB neurons and ≤ P15 for cortical pyramidal neurons. An endogenous 
neurosteroid tone is additionaly revealed by γ-CD in cortical interneurons at 
P7, but it dissipates by P20-24. The endogenous neurosteroid tone profile 
between P7 and P20-24 for these interneurons remains to be determined. The 
Right Y axis illustrates developmental changes to neurosteroid levels (arbitrary 
units and deduced by their impact on GABAAR phasic transmission) for VB 
neurons (blue lines), cortical neurons (green lines) and cortical interneurons 
(red lines). Dotted lines indicate that we do not have equivalent data on 
neurosteroid levels within these temporal windows. Note an arbitrary 
neurosteroid level of 0 here is used to infer a level of neurosteroid that is 
insufficient to influence phasic inhibition. 
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